Zydus Cadila gets FDA approval for Adalat CC, Questran generics
Drug firm Zydus Cadila has received the Food and Drug Administration’s nod for generic Adalat CC (nifedipine extended-release tablets), and for generic Questran (cholestyramine for oral suspension).
The Adalat CC generic will be available in 30-, 60- and 90-mg dosage strengths and is used to treat high blood pressure and angina (chest pain brought on by exercise or stress). It works to control blood pressure and reduce the number of angina attacks by relaxing blood vessels. The drug will be manufactured at the group’s manufacturing facility at Moraiya, Ahmedabad.
Zydus Cadila’s generic of Questran will be available in 4 g resin per pouch or scoopful. It is intended to be used with a proper diet to lower cholesterol in the blood. Lowering cholesterol helps decrease the risk for strokes and heart attacks. The drug will be manufactured at the group’s formulations manufacturing facility at Baddi.
The Adalat CC generic will be available in 30-, 60- and 90-mg dosage strengths and is used to treat high blood pressure and angina (chest pain brought on by exercise or stress). It works to control blood pressure and reduce the number of angina attacks by relaxing blood vessels. The drug will be manufactured at the group’s manufacturing facility at Moraiya, Ahmedabad.
Zydus Cadila’s generic of Questran will be available in 4 g resin per pouch or scoopful. It is intended to be used with a proper diet to lower cholesterol in the blood. Lowering cholesterol helps decrease the risk for strokes and heart attacks. The drug will be manufactured at the group’s formulations manufacturing facility at Baddi.